ArticleCureus2026
Incidence of Sepsis After Transrectal Ultrasound-Guided Prostate Biopsy in Dubai Tertiary Care Hospitals: A Multicenter Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-biopsy sepsis is a key safety concern after transrectal ultrasound-guided prostate biopsy (TRUS-Bx), yet data from the Middle East, where antimicrobial resistance patterns and prophylaxis practices may differ, remain limited. We assessed the incidence, timing, and risk factors for post-biopsy sepsis across three tertiary care hospitals in Dubai, United Arab Emirates.
methodsWe conducted a retrospective cohort study across three tertiary care hospitals within a single private network (2010-2021; n = 139). The primary outcome was clinically recorded sepsis after TRUS-Bx; for sepsis cases, time to onset (days) was recorded. Prophylaxis regimens were coded and grouped as single-agent versus combination. Associations were summarized as odds ratios (ORs) with 95% confidence intervals (CIs) and tested using Fisher's exact tests. Continuous variables were presented as mean ± standard deviation (SD) and median (interquartile range (IQR)). Age was abstracted in categories; when a mean age was reported, category midpoints were used.
resultsThe cohort was multinational (39 nationalities), with the largest groups being British (28.8%), American (8.6%), and Emirati (6.5%). Sepsis occurred in 21/138 (15.2%), averaging 1.75 cases/year. Among sepsis cases, the median time to onset was two days (IQR: 1-4; mean: 3.9; range: 1-22). Prophylaxis was documented in 133/139 patients: single-agent (58, 43.6%) versus combination (75, 56.4%). Sepsis risk did not differ by regimen group (p = 0.320) or across individual regimens (p = 0.81). Current smoking was associated with higher odds of sepsis (OR: 4.03; 95% CI: 1.31-12.39; p = 0.023), while hypertension was associated with lower odds (OR: 0.19; 95% CI: 0.053-0.69; p = 0.007). Diabetes showed no association (OR: 1.06; p = 1.00), and hyperlipidemia showed a non-significant trend (OR: 0.23; p = 0.061). Prostate-specific antigen (PSA) (n = 133) had a median of 7.74 (IQR: 5.74-15.0) and a mean of 15.70 ± 22.02. Prostate volume (n = 122) had a median of 39 mL (IQR: 30-54.8) and a mean of 45.0 ± 20.5.
conclusionIn this multinational cohort from Dubai's private sector, post-TRUS-Bx sepsis occurred in 15.2% of cases and typically presented within the first few days. Combination prophylaxis did not reduce risk compared with single-agent regimens. Current smoking was associated with increased odds of sepsis, whereas hypertension was associated with lower odds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.